Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع ادوية السختيان - sukhtian group - xylometazoline hcl 0.05 % - 0.05%

Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع ادوية السختيان - sukhtian group - xylometazoline hcl 0.10 % - 0.10%

Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

شركة أدوية الحكمة - hikma pharmaceuticals - cefixime 400 mg - 400 mg

Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

شركة أدوية الحكمة - hikma pharmaceuticals - cefixime (as trihydarte)400 mg - (as trihydarte)400 mg

Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع البتراء للمواد الطبية - petra drug store - somatropin 5.3 mg - 5.3 mg

Israel - English - Ministry of Health

j-c health care ltd - itraconazole - solution - itraconazole 10 mg/ml - itraconazole - itraconazole - sporanox oral solution is indicated for the treatment of oropharyngeal and esophageal candidiasis. prevention of fungal infection during neutropenia of immunodeficient patients.

Israel - English - Ministry of Health

kamada ltd, israel - human hepatitis b immunoglobulin - solution for injection - human hepatitis b immunoglobulin 500 iu - hepatitis b immunoglobulin - hepatitis b immunoglobulin - prevention of hepatitis b virus (hbv) re-infection in hbsag and hbv-dna negative adult patients at least one week after liver transplantation for hepatitis b induced liver failure.hbv-dna negative status should be confirmed within the last 3 months prior to olt. patients should be hbsag negative before treatment start.the concomitant use of adequate virostatic agents should be considered as standard of hepatitis b re-infection prophylaxis.

Israel - English - Ministry of Health

teva israel ltd - filgrastim - solution for injection / infusion - filgrastim 0.6 mg/ml - filgrastim - filgrastim - tevagrastim is indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes ) and for the reduction in the duration of neutropenia in patients undergoing myeloablative therapy followed by bone marrow transplantation considered to be at increased risk of prolonged severe neutropenia. the safety and efficacy of tevagrastim are similar in adults and children receiving cytotoxic chemotherapy. tevagrastim is indicated for the mobilisation of peripheral blood progenitor cells in normal donors (allogeneic pbpc). in patients children or adults with severe congenital neutropenia cyclic or idiopathic neutropenia with an absolute nuetrophil count (anc) less than or equal to 0.5 x 1000000000 /l and a history of severe or recurrent infections long term administration of tevagrastim is indicated to increase neutophil count and to reduce the incidence and duration of infection-related events. tevagrastim in indicated for the treatment of persistent neutopenia (anc less than or equal to 1.0 x 1000000000/l ) in patients with advanced hiv infection in order to reduce the risk of bacterial infections when other options to manage neutopenia are inappropriate.

Israel - English - Ministry of Health

padagis israel pharmaceuticals ltd, israel - alprazolam - tablets - alprazolam 0.5 mg - alprazolam - alprazolam - treatment of anxiety accompanied by depression. treatment of panic states with or without accompanying phobia.

Israel - English - Ministry of Health

padagis israel pharmaceuticals ltd, israel - alprazolam - tablets - alprazolam 1 mg - alprazolam - alprazolam - treatment of anxiety accompanied by depression. treatment of panic states with or without accompanying phobia.